MACSF

COMMUNIQUÉS West-GlobeNewswire

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
01/08/2025
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, [...]
OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First Case
01/08/2025
WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
01/08/2025
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for [...]
Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer
01/08/2025
Seasoned executive with proven track record driving growth and building customer focused teams to lead Milestone’s next phase of commercial execution ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone [...]
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
01/08/2025
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14 [...]
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
01/08/2025
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC [...]
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
01/08/2025
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]
IPG Health Introduces the Future of Market Research with ‘LivingMirror,’ an Always-On AI Focus Group for Healthcare
01/08/2025
Expanding network’s proprietary EPICC suite of tools for secure, AI-powered replicas of both HCPs and patients NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- For decades, market research has laid the foundation for deep [...]
Oculis Upsized Loan Facility to Access up to CHF 100 million
01/08/2025
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Oculis Upsized Loan Facility to Access up to CHF 100 million
01/08/2025
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
BrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
01/08/2025
LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
01/08/2025
LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
01/08/2025
Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for [...]
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial
31/07/2025
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) [...]
SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31/07/2025
DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
J-Star Holding Announces Closing of $5.0 Million Initial Public Offering
31/07/2025
TAICHUNG CITY, Taiwan, July 31, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications [...]
Nephros Schedules Second Quarter 2025 Financial Results Conference Call
31/07/2025
SOUTH ORANGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will [...]
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
31/07/2025
Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules [...]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
31/07/2025
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of [...]

Pages